Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Amplia Therapeutics and ANZGOG...
Tech clinical study

Amplia Therapeutics and ANZGOG Ovarian Cancer Study

Analysis based on 8 articles · First reported May 09, 2026 · Last updated May 09, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The announcement of a new clinical study for narmafotinib in ovarian cancer by Amplia Therapeutics is expected to positively impact the company's stock price due to the potential for expanding its drug's utility. This development also highlights the growing focus on unmet medical needs in oncology, which could attract further investment in the biotechnology and pharmaceutical sectors.

Pharmaceuticals Biotechnology Healthcare
Event Summary

Amplia Therapeutics and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) have entered into an agreement to conduct a new clinical study, the PRROSE trial, investigating Amplia Therapeutics' lead drug narmafotinib in ovarian cancer. The study, led by Dr. Gwo Yaw Ho of Monash Health and Monash University, will evaluate the safety and potential efficacy of narmafotinib in combination with standard-of-care chemotherapy for patients with high-grade serous ovarian cancer (HGSOC) who have not responded to platinum-based chemotherapy. This collaboration aims to address a significant unmet medical need and broaden the clinical utility of Amplia Therapeutics' FAK inhibitor program.

Key Actions
100 Amplia Therapeutics entered agreement Australia New Zealand Gynaecological Oncology Group
100 Australia New Zealand Gynaecological Oncology Group entered agreement Amplia Therapeutics
95 Amplia Therapeutics announced clinical study
Entities Involved
stock
Amplia Therapeutics
Amplia Therapeutics is the developer of narmafotinib and has entered into an agreement with Australia New Zealand Gynaecological Oncology Group (ANZGOG) to conduct a clinical study in ovarian cancer. This study broadens the clinical utility of its FAK inhibitor program.
Importance 100 Sentiment 70
ngo
Australia New Zealand Gynaecological Oncology Group
Australia New Zealand Gynaecological Oncology Group (ANZGOG) has partnered with Amplia Therapeutics to sponsor and coordinate the PRROSE trial, leveraging its clinical trials network to address unmet medical needs in gynecological cancers.
Importance 90 Sentiment 50
per
Gwo Yaw Ho
Dr. Gwo Yaw Ho of Monash Health and Monash University is the lead investigator for the PRROSE trial, spearheading the clinical study of narmafotinib in ovarian cancer.
Importance 70 Sentiment 30
per
Chris Burns
Dr. Chris Burns is the CEO and Managing Director of Amplia Therapeutics and expressed satisfaction with the collaboration, highlighting the potential of FAK inhibitors in ovarian cancer.
Importance 60 Sentiment 30
oth
Monash Health
Monash Health is one of the institutions where Dr. Gwo Yaw Ho, the lead investigator, is affiliated.
Importance 30 Sentiment 20
cnt
Australia
Australia is the location where Amplia Therapeutics is based and where the clinical study will be conducted.
Importance 10 Sentiment 0
cnt
New Zealand
New Zealand is part of the Australia New Zealand Gynaecological Oncology Group's (ANZGOG) network, where the clinical study will be conducted.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.